Gardasil supplemental application gets priority review designation
Merck & Co., Inc.’s supplemental Biologics License Application for use of Gardasil in women aged 27 through 45 has been accepted by the FDA and designated for priority review.
WHITEHOUSE STATION, New Jersey-Merck & Co., Inc.’s supplemental Biologics License Application for use of Gardasil in women aged 27 through 45 has been accepted by the FDA and designated for priority review. Gardasil [human papillomavirus quadrivalent (types 6, 11, 16, 18) vaccine, recombinant] is currently indicated for girls and women age 9 through 26 for the prevention of cervical cancer, precancerous or dysplastic lesions, and genital warts caused by HPV types 6, 11, 16, and 18.
Highlighting Insights From the Marginal Zone Lymphoma Workshop
Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.
